IMPLANET: First JAZZ Implants Performed in China
IMPLANET, a company specializing in spinal implants, announces the first placements of its JAZZ system in China, marking a major turning point in its international expansion strategy.
Successful Registration and Initial Implantations
In collaboration with Sanyou Medical, IMPLANET has completed the registration of its JAZZ range in the Chinese market, the largest in terms of volume potential. Following the approval from the CFDA in July 2025, the first implants were delivered in September and showcased at the Chinese Orthopedic Association's congress in November. The initial surgeries were performed in Hainan by Dr. Huanxiang Chen after intensive training in France.
Intensive Skill Transfer and Training
The success of this launch relies on an intensive skill transfer, with a two-month training program for Dr. Chen in France. This program was supervised by renowned experts, ensuring the use of the JAZZ® system according to international standards of quality and safety. IMPLANET and Sanyou Medical aim for a structured and gradual deployment, with further surgeries planned in Shanghai and Beijing.
Strategic Milestone Acknowledged by CEO
Ludovic Lastennet, CEO of IMPLANET, praises this advancement as a crucial strategic step. The Chinese approval and the successful initial operations confirm the clinical value of the system in a key market. The upcoming installations in Shanghai and Beijing demonstrate IMPLANET's ambition for a sustainable deployment in China.
